Batt Sarah M, Burke Christopher E, Moorey Alice R, Besra Gurdyal S
Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Cell Surf. 2020 Sep 2;6:100044. doi: 10.1016/j.tcsw.2020.100044. eCollection 2020 Dec.
, the bacterium responsible for tuberculosis, is the global leading cause of mortality from an infectious agent. Part of this success relies on the unique cell wall, which consists of a thick waxy coat with tightly packed layers of complexed sugars, lipids and peptides. This coat provides a protective hydrophobic barrier to antibiotics and the host's defences, while enabling the bacterium to spread efficiently through sputum to infect and survive within the macrophages of new hosts. However, part of this success comes at a cost, with many of the current first- and second-line drugs targeting the enzymes involved in cell wall biosynthesis. The flip side of this coin is that resistance to these drugs develops either in the target enzymes or the activation pathways of the drugs, paving the way for new resistant clinical strains. This review provides a synopsis of the structure and synthesis of the cell wall and the major current drugs and targets, along with any mechanisms of resistance.
结核分枝杆菌是导致全球因感染性病原体死亡的首要原因。其成功的部分原因在于独特的细胞壁,它由一层厚厚的蜡质外壳组成,其中紧密排列着复合糖、脂质和肽层。这层外壳为抗生素和宿主防御提供了保护性疏水屏障,同时使细菌能够通过痰液有效传播,在新宿主的巨噬细胞内感染并存活。然而,这种成功也有代价,目前许多一线和二线药物都针对参与细胞壁生物合成的酶。问题在于,对这些药物的耐药性会在靶酶或药物激活途径中产生,为新的耐药临床菌株铺平道路。本综述概述了细胞壁的结构和合成、当前主要药物和靶点,以及任何耐药机制。